Our read is that using extra virgin olive oil is well supported for its potential health benefits, provided quality and usage considerations are met.
Our sources generally support the use of extra virgin olive oil for its potential to improve various health markers, including weight management, blood pressure, blood sugar, cholesterol, heart health, brain health, and mood, as noted by Bryan Johnson.
However, there are significant caveats regarding the quality and authenticity of olive oil, with Paul Saladino and Bryan Johnson highlighting issues like adulteration and misleadingly low quality.
Experts recommend prioritizing high-polyphenol, high-antioxidant extra virgin olive oil, storing it properly, and avoiding its use for cooking due to concerns about linoleic acid content and oxidation.
To use extra virgin olive oil, prioritize high-polyphenol, high-antioxidant varieties, such as unprocessed extra virgin olive oil from early harvests with high polyphenol content (>= 500 mg/ml), as suggested by Paul Saladino. Store olive oil in opaque glass containers to prevent degradation and avoid plastic leaching, according to Paul Saladino. Bryan Johnson recommends consuming extra virgin olive oil with food to prevent potential side effects and notes that clinical trials typically use 25-60 mL per day. Peter Attia includes extra virgin olive oil in his daily salad. Paul Saladino advises against using extra virgin olive oil for cooking.
Paul Saladino argues that olive oil is not healthier than animal fat and lacks special nutritional magic, also stating that most available olive oils are misleadingly low quality. He advises against using extra virgin olive oil for cooking due to its linoleic acid content (8-25%), which is prone to oxidation when heated, and prefers animal fats over olive oil for this reason. Paul Saladino also believes high oleic acid intake from olive oil is not beneficial and does not protect against obesity, based on mouse studies. He highlights purity and quality issues, noting that many olive oils are adulterated or have high peroxide values, with one study finding only 20% of Argentinian virgin olive oils had acceptable quality. Bryan Johnson also acknowledges that the quality and authenticity of extra virgin olive oil can be unreliable, with some being adulterated. Paul Saladino suggests that consuming olive oil with carbohydrates promotes de novo lipogenesis, hindering carbohydrate burning, and prefers coconut oil due to its saturated fat content and lower likelihood of adulteration. Peter Attia warns that using antioxidant-depleted olive oil may negatively affect the endothelium. Paul Saladino also notes that high monounsaturated fatty acid oils, like olive oil, may be associated with obesity in observational studies and could increase visceral fat in mouse models. The PRIIMED trial, which investigated olive oil consumption, indicated statistically significant increases in obesity and diabetes among those consuming more olive oil, though it had issues with randomization and was initially retracted.
A change in the verdict would require more consistent evidence regarding the quality and authenticity of commercially available extra virgin olive oil, as well as further research clarifying the impact of its linoleic acid content and oleic acid intake on human health, particularly concerning obesity and metabolic health. Additionally, more robust clinical trials addressing the potential for de novo lipogenesis when consumed with carbohydrates would be influential.
The effect size is large enough to matter clinically, not just statistically.
Benefits hold across the populations where it's been tested.
The intervention improves the primary outcome at standard doses in healthy adults.
The intervention improves the primary outcome at standard doses in healthy adults.
The effect size is large enough to matter clinically, not just statistically.
The headline effect shrinks once you account for trial quality.
Most of the support comes from short or small studies.
Confounding and publication bias inflate the apparent benefit.
Confounding and publication bias inflate the apparent benefit.
The headline effect shrinks once you account for trial quality.